Phibro Animal Health Corporation
HealthcareNASDAQ:PAHC · NASDAQ Global Market
+$0.27 today
Vol 0.18M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
16.9%
avg 44.2%
ROIC
7.2%
avg 9.9%
ROA
3.5%
avg 7.0%
Analysis
ROE is currently the strongest return metric at 16.9% versus its period average of 44.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jack Clifford Bendheim | Chairman, President & Chief Executive Officer | $5.12M | — | 79 | $56,152.00 | 0.14% |
Larry L. Miller | Chief Operating Officer | $2.42M | — | 62 | $35,184.00 | 0.09% |
Glenn C. David | Chief Financial Officer | $1.27M | — | 54 | $52,317.00 | 0.13% |
Daniel Bendheim | Executive Vice President of Corporate Strategy & Director | $1.12M | — | 54 | $56,152.00 | 0.14% |
Judith A. Weinstein | Senior Vice President, General Counsel & Corporate Secretary | $1.04M | — | 57 | $3,447.00 | <0.01% |
Todd Armstrong | President of North American Region | — | — | — | — | — |
Lisa A. Escudero | Senior Vice President of Human Resources | — | — | 64 | $2,152.00 | <0.01% |
Jonathan Bendheim | Executive Vice President of Global Technology & People and Director | — | — | 50 | $56,152.00 | 0.14% |
Ramon Fuenmayor | President South America Region | — | — | — | — | — |
Samson Li | President of Asia Pacific Region | — | — | 54 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$317,700.00
Sells
122
$32.00M
Net Sentiment
$31.68M
Net selling
Most Active
BENDHEIM JACK
122 transactions
1–10 of 123
Analysis
Insiders reported 1 buys worth $317,700.00 and 122 sells worth $32.00M over the last 12 months. That adds up to net selling of $31.68M. BENDHEIM JACK was the most active insider with 122 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +87.2% | +8.1% (15yr)1 analysts |
| Revenue | N/A | N/A | +4.6% | +5.6% (15yr)2 analysts |
| Net Income | N/A | N/A | +105.2% | +8.2% (15yr)2 analysts |
| EBIT | N/A | N/A | +21.1% | +2.4% (15yr)2 analysts |
Analysis
Recent growth has been strongest in Net Income at +105.2% over three years. Forward estimates point to Net Income at +8.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Organon & Co.
NYSE:OGN
$3.53B
Avadel Pharmaceuticals plc
AVDL
$2.12B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.03B
Pediatrix Medical Group, Inc.
NYSE:MD
$2.00B
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
$1.86B
Alvotech
NASDAQ:ALVO
$1.30B
MannKind Corporation
NASDAQ:MNKD
$1.13B
Evotec SE
NASDAQ:EVO
$966.11M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
BGM Group Ltd.
NASDAQ:BGM
$75.23M
Who manages PAHC?
Phibro Animal Health Corporation (PAHC) lists 10 active executives. The top listed executive is Glenn C. David, Chief Financial Officer.
Are PAHC insiders buying or selling?
Recent insider activity shows net selling of $33.23M.
Explore More
Continue the stock analysis
Jump to another research area for this company.